Predictive factors for the clinical effect of PD-1/PD-L1 checkpoint inhibitors in treatment of hepatocellular carcinoma / 临床肝胆病杂志
Journal of Clinical Hepatology
; (12): 1389-1392, 2020.
Article
em Zh
| WPRIM
| ID: wpr-822198
Biblioteca responsável:
WPRO
ABSTRACT
At present, there is still a lack of uniform treatment strategies for hepatocellular carcinoma (HCC). Immunotherapy, especially PD-1/PD-L1 checkpoint inhibitors, is a novel therapy for HCC and can bring survival benefits to patients with advanced HCC. However, research data show that only a small number of HCC patients can benefit from this treatment regimen. To date, few biomarkers have been reported to predict the clinical effect of PD-1/PD-L1 checkpoint inhibitors in HCC patients. This article reviews the biomarkers studied for HCC and other tumors and explores the possible predictive factors for the clinical effect of PD-1/PD-L1 checkpoint inhibitors in HCC, in order to optimize the selection of treatment population and improve the clinical effect of PD-1/PD-L1 checkpoint inhibitors in the treatment of HCC.
Texto completo:
1
Base de dados:
WPRIM
Tipo de estudo:
Prognostic_studies
Idioma:
Zh
Revista:
Journal of Clinical Hepatology
Ano de publicação:
2020
Tipo de documento:
Article